ம்ட் பல்கலைக்கழகம் ஆஃப் சிகாகோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

VT, No Matter Its Source, Benefits From Early Catheter Ablation: PAUSE-SCD

VT, No Matter Its Source, Benefits From Early Catheter Ablation: PAUSE-SCD
tctmd.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tctmd.com Daily Mail and Mail on Sunday newspapers.

Roderick tungPaula friedmanHeart rhythm societyMd university of chicagoMayo clinicரோடெரிக் துங்பால ப்ரைட்மேன்இதயம் தாளம் சமூகம்ம்ட் பல்கலைக்கழகம் ஆஃப் சிகாகோமயோ சிகிச்சையகம்

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

May 16, 2021 Ultrasound-based renal denervation (Paradise; ReCor Medical) significantly lowers systolic blood pressure when compared with a sham procedure in patients with resistant hypertension treated on a background of antihypertensive therapy, the RADIANCE-HTN TRIO shows. Renal denervation reduced daytime ambulatory systolic blood pressure by 8.0 mm Hg compared with a 3.0-mm Hg reduction observed in patients treated with the sham procedure, a median between-group difference of 4.5 mm Hg ( P = 0.02). Additionally, there were significant between-group reductions in 24-hour ambulatory systolic blood pressure, nighttime ambulatory systolic blood pressure, and office- and home-based systolic blood pressure. “I don’t want to be perceived as overselling anything, but sham-controlled controls are great for determining if there is an effect or not,” senior investigator Ajay Kirtane, MD (NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY), told TCT

New yorkUnited statesUniversity of chicagoRush university medical centerAjay kirtaneHomburg saarGeorge bakrisKim williamsLucas lauderMd rush university medical centerMd university of chicagoAmerican college of cardiologyOffice systolicPresbyterian columbia university irving medical centerMd saarland universityRecor medical

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

May 11, 2021 The addition of finerenone to standard medical therapy significantly reduces the risk of cardiovascular mortality and other cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes, according to topline results from FIGARO-DKD announced this week. Bayer, the maker of the investigational mineralocorticoid receptor antagonist (MRA), announced that the large-scale study met its primary endpoint reduction in the risk of first occurrence of CV mortality, MI, stroke, or heart failure hospitalization in the approximately 7,400 patients randomized in the trial. The positive study is the second trial showing a benefit of finerenone in patients with CKD and type 2 diabetes. In the FIDELIO-DKD trial, led by George Bakris, MD (University of Chicago, IL), finerenone reduced the risk of kidney failure or death from renal causes, the study’s primary endpoint, and reduced the risk of CV mortality, MI, stroke, or heart failure hospitalization. Unlike

George bakrisEuropean society of cardiology congressMd university of chicagoAmerican college of cardiologyEuropean medicines agencyDrug administrationEuropean societyAmerican collegeஜார்ஜ் பக்ரிஸ்ஐரோப்பிய சமூகம் ஆஃப் இருதயவியல் காங்கிரஸ்ம்ட் பல்கலைக்கழகம் ஆஃப் சிகாகோஅமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல்ஐரோப்பிய சமூகம்அமெரிக்கன் கல்லூரி